AMPH · Company research
Amphastar Pharmaceuticals, Inc. (AMPH): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
18records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Amphastar Pharmaceuticals (NASDAQ:AMPH) Share Price Crosses Above 50 Day Moving Average - Should You Sell? - MarketBeat | Amphastar Pharmaceuticals (NASDAQ:AMPH) Share Price Crosses Above 50 Day Moving Average - Should You Sell? MarketBeat | View source ↗ | MarketBeat | Oct 13, 2026 | neutral | 0 | 0.6 |
| Amphastar Pharmaceuticals, Inc. (AMPH) Stock Price, News, Quote & History - Yahoo! Finance Canada | Amphastar Pharmaceuticals, Inc. (AMPH) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 9, 2026 | neutral | 0 | 0.6 |
| Amphastar Pharmaceuticals, Inc. (AMPH) Stock Forecasts - Yahoo! Finance Canada | Amphastar Pharmaceuticals, Inc. (AMPH) Stock Forecasts Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 7, 2026 | neutral | 0 | 0.6 |
| Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock? | Zacks highlights Amphastar Pharmaceuticals (AMPH) as an attractive value stock with a Zacks Rank #2 (Buy) rating and an 'A' grade for Value. The stock trades at a P/E ratio of 7.81 compared to its industry average of 15.87, along with favorable P/B and P/S ratios, suggesting it is currently undervalued by the market. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 1 | 1 |
| Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock? | Zacks highlights Amphastar Pharmaceuticals (AMPH) as an attractive value stock with a Zacks Rank #2 (Buy) rating and an 'A' grade for Value. The stock trades at a P/E ratio of 7.81 compared to its industry average of 15.87, along with favorable P/B and P/S ratios, suggesting it is currently undervalued by the market. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 1 | 1 |
| Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock? - Yahoo Finance | Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 6, 2026 | neutral | 0 | 0.6 |
| Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Rating Raised to Strong-Buy at Wall Street Zen - MarketBeat | Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Rating Raised to Strong-Buy at Wall Street Zen MarketBeat | View source ↗ | MarketBeat | Oct 3, 2026 | neutral | 0 | 0.6 |
| Amphastar: 2 Years Since My Last Hold Call, I Remain On Sidelines (NASDAQ:AMPH) - Seeking Alpha | Amphastar: 2 Years Since My Last Hold Call, I Remain On Sidelines (NASDAQ:AMPH) Seeking Alpha | View source ↗ | Seeking Alpha | Sep 30, 2026 | neutral | 0 | 0.6 |
| 3 Reasons to Avoid AMPH and 1 Stock to Buy Instead - Yahoo Finance | 3 Reasons to Avoid AMPH and 1 Stock to Buy Instead Yahoo Finance | View source ↗ | Yahoo Finance | Sep 24, 2026 | neutral | 0 | 0.6 |
| At $25 a share, Amphastar Pharmaceuticals (AMPH) CFO William Peters sold 4,139 shares. - Stock Titan | At $25 a share, Amphastar Pharmaceuticals (AMPH) CFO William Peters sold 4,139 shares. Stock Titan | View source ↗ | Stock Titan | Sep 23, 2026 | neutral | 0 | 0.6 |
| Amphastar (NASDAQ: AMPH) exec plans 4,139-share Rule 144 sale - Stock Titan | Amphastar (NASDAQ: AMPH) exec plans 4,139-share Rule 144 sale Stock Titan | View source ↗ | Stock Titan | Sep 21, 2026 | neutral | 0 | 0.6 |
| Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference - Stock Titan | Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference Stock Titan | View source ↗ | Stock Titan | Sep 1, 2026 | neutral | 0 | 0.6 |
| Amphastar Pharmaceuticals (NASDAQ:AMPH) Stands Out as a Quality Investing Candidate - ChartMill | Amphastar Pharmaceuticals (NASDAQ:AMPH) Stands Out as a Quality Investing Candidate ChartMill | View source ↗ | ChartMill | Aug 15, 2026 | neutral | 0 | 0.6 |
| Amphastar Pharmaceuticals (AMPH) Stock Rebound Meets Margin Pressure And Valuation Gap - Simply Wall Street | Amphastar Pharmaceuticals (AMPH) Stock Rebound Meets Margin Pressure And Valuation Gap Simply Wall Street | View source ↗ | Simply Wall Street | Aug 8, 2026 | neutral | 0 | 0.6 |
| Amphastar Pharmaceuticals (NASDAQ:AMPH) Screens as a High-Quality Stock with Deep Value Appeal - ChartMill | Amphastar Pharmaceuticals (NASDAQ:AMPH) Screens as a High-Quality Stock with Deep Value Appeal ChartMill | View source ↗ | ChartMill | Jul 18, 2026 | neutral | 0 | 0.6 |
| Amphastar stock slips on FDA warning letter (AMPH:NASDAQ) - Seeking Alpha | Amphastar stock slips on FDA warning letter (AMPH:NASDAQ) Seeking Alpha | View source ↗ | Seeking Alpha | Jul 8, 2026 | neutral | 0 | 0.6 |
| Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Lower Today - StockStory | Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Lower Today StockStory | View source ↗ | StockStory | May 14, 2026 | neutral | 0 | 0.6 |
| Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q1 CY2026 Sales Expectations, Stock Drops - StockStory | Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q1 CY2026 Sales Expectations, Stock Drops StockStory | View source ↗ | StockStory | May 7, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.